Work

1695P Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)

Year: 2024

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.1788

Authors: U.N. Vaishampayan, A.J. Zurita Saavedra, K. Beckermann, A. Chain, D. Vickery, Y. Zhang, R. Perini, D.F. McDermott

Institutions: Michigan Medicine, U-M Rogel Cancer Center, The University of Texas MD Anderson Cancer Center, Vanderbilt University Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), Beth Israel Deaconess Medical Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4402704825

FWCI: 0.29

Cites:

Cited by: 1

Related to: 10